Skip to content

Rare Disease Targeted Sequencing

Gene panels for rare disease

A focused method for testing known disease genes

Benefits of Targeted Sequencing for Rare Diseases

Targeted sequencing can provide the researcher a focused set of genes to investigate when a specific condition or disease state is suspected. The investigator can identify regions of interest and select panels to interrogate known disease-causing genes appropriate to the phenotype. With both research use only (RUO) tools and an IVD solution for clinical use, options are plentiful for further targeted analysis.

Targeted Sequencing Panels for Rare Diseases

Cystic Fibrosis Testing (For IVD-Use)

The TruSight Cystic Fibrosis 139-Variant Assay is an FDA-cleared, CE-IVD-marked NGS test designed to detect 139 CFTR variants as defined in the CFTR2 database. Other methods test only for those variants most commonly found in Caucasians, potentially missing CF-causing variants across broader ethnic groups. The assay offers the largest CF variant panel to overcome this bias and provide comprehensive detection across diverse demographics.1

Learn More
Comprehensive Sequencing of Disease-Related Genes

The TruSight One Sequencing Panel provides comprehensive coverage of > 4800 disease-associated genes, while the TruSight One Expanded Sequencing Panel targets ~1900 additional genes with recent disease associations in the scientific literature.

Learn More
Inherited Disease Gene Sequencing

TruSight Inherited Disease was developed in collaboration with Dr. Stephen Kingsmore during his tenure at Children's Mercy Hospital (CMH) for Pediatric Genomic Medicine, Dr. Carol Saunders at CMH, and Dr. Hilger Ropers at the Max Planck Institute. The panel includes 552 genes focused on severe, recessive childhood diseases and intellectual disability.

Learn More
Neurological Disease Gene Sequencing

The TruSeq Neurodegeneration Panel covers 118 risk genes associated with common neurodegenerative diseases, including Alzheimer’s disease, Parkinson's disease, and others. Leading researchers in the neuroscience community contributed their expertise to the design and development of this sequencing panel.

Learn More
Gaining Insight into Genetic Disease

Dr. Kenjiro Kosaki furthers his clinical research and expands the genetic analysis services he provides with the TruSight One Sequencing Panel. Learn why he thinks genomic technology will drastically change how we assess patients suffering from undiagnosed disorders.

Read Interview

Recent Genetic & Rare Disease Articles

Coordinating Research and Efforts in China’s Rare Disease Community
Coordinating Research and Efforts in China’s Rare Disease Community

Illumina supports the release of a landmark consensus on whole-genome sequencing in the diagnosis of genetic diseases in newborns

Read Article
Whole-Genome Sequencing as an Asset for Life
Whole-Genome Sequencing as an Asset for Life

Whole-genome and whole-exome sequencing-based consumer genomics companies are entering the market, offering a genomic view for life-long genetic assessment.

Read Interview
Kansas City Lights the Night with a New Research Institute
Kansas City Lights the Night with a New Research Institute

Genomic sequencing is giving families hope in the face of uncertainty at Children’s Mercy Hospital in Kansas City

Read Article

Related Solutions

Illumina DNA Prep with Enrichment

This assay forms the foundation of the sequencing technology behind our gene panels. It features our fastest and most flexible targeted sequencing technology.

NextSeq 2000 System

This sequencer introduces over 75 breakthrough innovations to deliver a faster, more intuitive experience in next-generation sequencing.

WGS for Rare Disease

While targeted sequencing can identify important genomic insights, whole-genome sequencing (WGS) is the most comprehensive assay for rare disease genomics.

References
  1. Hughes EE, Stevens CF, Saavedra-Matiz CA, et al. Clinical sensitivity of cystic fibrosis mutation panels in a diverse population. Hum Mutat. 2016;37(2):201-208. doi:10.1002/humu.22927